Cover Image

Levodopa versus levodopa sparing in early parkinson's disease: can we meet halfway?

Monotherapy is the recommended initial treatment for early Parkinson's disease. The pharmacological options for initial treatment include dopaminergic agonists, monoamine oxidase B inhibitors, and levodopa formulations. Several factors should be considered when selecting the optimal treatment,...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mayela Rodríguez-Violante (Author), Ana J. Hernández-Medrano (Author), Amin Cervantes-Arriaga (Author), Cesarina Torres-Vásquez (Author), Dioselina Tristán-Samaniego (Author), Carolina Zepeda-Salazar (Author), Victoria Cerino-Palomino (Author), Arturo Abundes-Velasco (Author)
Format:	Book
Published:	Permanyer, 2024-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation
by: Yi ZM, et al.
Published: (2018)

Levodopa-induced Dyskinesias in Parkinson's Disease: Current Knowledge and Future Scenarios
by: Francesca Morgante
Published: (2015)

Parkinson's disease: general features, effects of levodopa treatment and future directions
by: Marco Aurelio M Freire, et al.
Published: (2010)

Levodopa in Parkinson's Disease: A Review of Population Pharmacokinetics/Pharmacodynamics Analysis
by: Amélie Marsot, et al.
Published: (2017)

The human experience with intravenous levodopa
by: Shan H Siddiqi, et al.
Published: (2016)

Analysis of Genetic and Non-genetic Predictors of Levodopa Induced Dyskinesia in Parkinson's Disease
by: Alfonsina Tirozzi, et al.
Published: (2021)

Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications
by: Urszula Adamiak-Giera, et al.
Published: (2021)

Benign Hereditary Chorea: Response to Levodopa
by: J Gordon Millichap
Published: (2012)

Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy
by: Annus Á, et al.
Published: (2017)

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease
by: Sharma VD, et al.
Published: (2018)

In situ thermosensitive gel of levodopa: Potential formulation for nose to brain delivery in Parkinson disease
by: Shohreh Alipour, et al.
Published: (2020)

Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson's disease
by: Sebastiano Gangemi, et al.
Published: (2003)

Xanthonychia Due to Staining From Carbidopa-Levodopa
by: Jonathan Kyle Hwang, et al.
Published: (2023)

The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients
by: Faddoul L, et al.
Published: (2018)

Co-Application of C16 and Ang-1 Improves the Effects of Levodopa in Parkinson Disease Treatment
by: Fu XX, et al.
Published: (2022)

Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats
by: Song L,Yuan W, et al.
Published: (2012)

Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease
by: Marianne Luinstra, et al.
Published: (2019)

The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson’s Disease: A Systematic Review
by: Zhang XR, et al.
Published: (2020)

Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence
by: Bette S, et al.
Published: (2018)

Dramatic Improvement in Juvenile Parkinsonism after Levodopa Treatment in a Patient Negative for the PANK2 Mutation
by: Syuan-Yu Hong, et al.
Published: (2016)

Istradefylline: A novel agent in the treatment of "off" episodes associated with levodopa/carbidopa use in Parkinson disease
by: Lauren Cummins, et al.
Published: (2022)

Levodopa Dose-Limiting Dyskinesias in Treatment of Segawa Disease
by: J Gordon Millichap
Published: (2012)

Levodopa-based device-aided therapies for the treatment of advanced Parkinson's disease: a social return on investment analysis
by: Inez Denham, et al.
Published: (2024)

A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's disease
by: Debleena Guin, et al.
Published: (2017)

Large left posterior fossa meningioma presenting with quadriplegia in a woman with history of carbidopa-levodopa resistant parkinsonism
by: Antonio Jose Reyes, et al.
Published: (2019)

Basal ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia
by: Pedro eBarroso Chinea, et al.
Published: (2010)

Levodopa-benserazide Interaction with Enteral Nutrition: A Case Report
by: Foroud Shahbazi, et al.
Published: (2018)

Spray Dried Levodopa-Doped Powder Potentially for Intranasal Delivery
by: Xuan Liu, et al.
Published: (2022)

Design and Development of Levodopa Loaded Polymeric Nanoparticles for Intranasal Delivery
by: Mohd Zulhelmy Ahmad, et al.
Published: (2022)

Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson's Disease: A Perspective Through Preclinical and Clinical Evidence
by: Ritam Bandopadhyay, et al.
Published: (2022)

Improving treatment for Parkinson's disease: Harnessing photothermal and phagocytosis-driven delivery of levodopa nanocarriers across the blood-brain barrier
by: Kaili Liang, et al.
Published: (2024)

Effects of blackberry (Morus nigra) fruit juice on levodopa-induced dyskinesia in a mice model of Parkinson's disease
by: Fahimi Z, et al.
Published: (2018)

Levodopa-Entacapone-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease: A Single Center Real-World Experience
by: Szabolcs Szatmári, et al.
Published: (2024)

Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: Observations and Dilemmas after 10 Years of Real-Life Experience
by: József Attila Szász, et al.
Published: (2022)

NANOFORMULASI LEVODOPA MENGGUNAKAN NANOSTRUCTURED LIPID CARRIER BERBASIS SETIL PALMITAT DAN ASAM OLEAT SEBAGAI KANDIDAT OBAT PARKINSON
by: Raden Melvin Fauzan Idat, -
Published: (2023)

Modafinil alleviates levodopa-induced excessive nighttime sleepiness and restores monoaminergic systems in a nocturnal animal model of Parkinson's disease
by: Rina Ando, et al.
Published: (2018)

3D Printed Mini-Floating-Polypill for Parkinson's Disease: Combination of Levodopa, Benserazide, and Pramipexole in Various Dosing for Personalized Therapy
by: Hellen Windolf, et al.
Published: (2022)

Predicting the longitudinal changes of levodopa dose requirements in Parkinson's disease using item response theory assessment of real‐world Unified Parkinson's Disease Rating Scale
by: Dongwoo Chae, et al.
Published: (2021)

Pharmaceutical and pharmacokinetic evaluation of a newly formulated multiparticulate matrix of levodopa and carbidopa
by: Emelia Priscilla Imbeah, et al.
Published: (2022)

Proteomics Reveal the Inhibitory Mechanism of Levodopa Against Esophageal Squamous Cell Carcinoma
by: Zhenzhen Li, et al.
Published: (2020)